Western blot analysis of extracts from C6 and NIH/3T3 cells, starved for 18 hours and either untreated or PDGF-treated (50ng/ml, 20 minutes), using Phospho-SHP-2 (Tyr542) Antibody (upper) or control SHP-2 Antibody #3752 (lower).
Immunohistochemical analysis of paraffin-embedded human breast carcinoma using SHP-2 (D50F2) Rabbit mAb (left) or SHP-2 Antibody (right). These two antibodies detect independent, unique epitopes on human SHP-2. The similar staining patterns obtained with both antibodies help to confirm the specificity of the staining.
Western blot analysis of total cell lysates from NIH/3T3 cells, serum-starved overnight and treated with PDGF (#9909) for 5 minutes, using Phospho-SHP-2 (Tyr580) Antibody (upper) or control SHP-2 Antibody #3752 (lower).
After the primary antibody is bound to the target protein, a complex with HRP-linked secondary antibody is formed. The LumiGLO® is added and emits light during enzyme catalyzed decomposition.
Immunohistochemical analysis of paraffin-embedded human breast carcinoma using SHP-2 (D50F2) Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded K-562 cell pellet (left, high-expressing) or Saos-2 cell pellet (right, low-expressing) using SHP-2 (D50F2) Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded human colon carcinoma using SHP-2 (D50F2) Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded human melanoma using using SHP-2 (D50F2) Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded mouse ovary using SHP-2 (D50F2) Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded human endometrioid adenocarcinoma using SHP-2 (D50F2) Rabbit mAb.
Western blot analysis of extracts from control 293T cells (lane 1) or SHP-2 knockout 293T cells (lane 2) using SHP-2 (D50F2) Rabbit mAb (upper) or β-Actin (D6A8) Rabbit mAb #8457 (lower). The absence of signal in the SHP-2 knockout 293T cells confirms specificity of the antibody for SHP-2.
Western blot analysis of extracts from various cell lines using SHP-2 (D50F2) Rabbit mAb.
|Phospho-SHP-2 (Tyr542) Antibody 3751||20 µl||
||H M R||72||Rabbit|
|SHP-2 (D50F2) Rabbit mAb 3397||20 µl||
||H M R Mk||72||Rabbit IgG|
|Phospho-SHP-2 (Tyr580) Antibody 3703||20 µl||
||H M R||72||Rabbit|
|Anti-rabbit IgG, HRP-linked Antibody 7074||100 µl||
The SHP-2 Antibody Sampler Kit provides an economical means to evaluate levels of SHP-2 protein phosphorylated at the specified sites, as well as total SHP-2 levels. The kit contains enough primary and secondary antibody to perform two western blot experiments per antibody.
SHP-2 (D50F2) Rabbit mAb detects endogenous levels of total SHP-2 protein. Phospho- (Tyr542) SHP-2 Antibody detects endogenous SHP-2 only when phosphorylated at the specified at Tyr542. Phospho- SHP-2 (Tyr580) Antibody detects endogenous level of SHP2 only when phosphorylated at Tyr580. Some cross-reactivity with phosphorylated RTKs may occur. See individual product webpages for more information.
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to the carboxy-terminal sequence of human SHP-2. Polyclonal antibodies are produced by immunizing animals with synthetic phosphopeptides corresponding to residues surrounding Tyr542 and Tyr580 of human SHP-2 protein. Antibodies are purified by protein A and peptide affinity chromatography.
SHP-2 (PTPN11) is a ubiquitously expressed, nonreceptor protein tyrosine phosphatase (PTP). It participates in signaling events downstream of receptors for growth factors, cytokines, hormones, antigens, and extracellular matrices in the control of cell growth, differentiation, migration, and death (1). Activation of SHP-2 and its association with Gab1 is critical for sustained Erk activation downstream of several growth factor receptors and cytokines (2). In addition to its role in Gab1-mediated Erk activation, SHP-2 attenuates EGF-dependent PI3 kinase activation by dephosphorylating Gab1 at p85 binding sites (3). SHP-2 becomes phosphorylated at Tyr542 and Tyr580 in its carboxy-terminus in response to growth factor receptor activation (4). These phosphorylation events are thought to relieve basal inhibition and stimulate SHP-2 tyrosine phosphatase activity (5). Mutations in the corresponding gene result in a pair of clinically similar disorders (Noonan syndrome and LEOPARD syndrome) that may result from abnormal MAPK regulation (6).
Explore pathways + proteins related to this product.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.